Search Results - "Lankes, A"

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study by Zamarin, Dmitriy, Burger, Robert A, Sill, Michael W, Powell, Jr, Daniel J, Lankes, Heather A, Feldman, Michael D, Zivanovic, Oliver, Gunderson, Camille, Ko, Emily, Mathews, Cara, Sharma, Sudarshan, Hagemann, Andrea R, Khleif, Samir, Aghajanian, Carol

“…Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone…”
Get full text

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) by Santin, Alessandro D., Deng, Wei, Frumovitz, Michael, Buza, Natalia, Bellone, Stefania, Huh, Warner, Khleif, Samir, Lankes, Heather A., Ratner, Elena S., O'Cearbhaill, Roisin E., Jazaeri, Amir A., Birrer, Michael

“…Patients with persistent/recurrent cervical cancer following platinum-based chemotherapy have limited therapeutic options. The Gynecologic-Oncology-Group…”
Get full text

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study by Norquist, Barbara M, Brady, Mark F, Harrell, Maria I, Walsh, Tom, Lee, Ming K, Gulsuner, Suleyman, Bernards, Sarah S, Casadei, Silvia, Burger, Robert A, Tewari, Krishnansu S, Backes, Floor, Mannel, Robert S, Glaser, Gretchen, Bailey, Cheryl, Rubin, Stephen, Soper, John, Lankes, Heather A, Ramirez, Nilsa C, King, Mary Claire, Birrer, Michael J, Swisher, Elizabeth M

“…We hypothesized that mutations in homologous recombination repair (HRR) genes beyond and improve outcomes for ovarian carcinoma patients treated with platinum…”
Get full text

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study by McMeekin, D Scott, Tritchler, David L, Cohn, David E, Mutch, David G, Lankes, Heather A, Geller, Melissa A, Powell, Matthew A, Backes, Floor J, Landrum, Lisa M, Zaino, Richard, Broaddus, Russell D, Ramirez, Nilsa, Gao, Feng, Ali, Shamshad, Darcy, Kathleen M, Pearl, Michael L, DiSilvestro, Paul A, Lele, Shashikant B, Goodfellow, Paul J

“…The clinicopathologic significance of mismatch repair (MMR) defects in endometrioid endometrial cancer (EEC) has not been definitively established. We…”
Get full text

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study by Farley, John, Prof, Brady, William E, PhD, Vathipadiekal, Vinod, PhD, Lankes, Heather A, PhD, Coleman, Robert, Prof, Morgan, Mark A, Prof, Mannel, Robert, Prof, Yamada, S Diane, Prof, Mutch, David, Prof, Rodgers, William H, Prof, Birrer, Michael, MD, Gershenson, David M, MD

“…Summary Background Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could be targeted to control tumour growth. We…”
Get full text

Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial by MATEI, Daniela, SILL, Michael W, PETRICOIN, Emanuel F, BIRRER, Michael J, LANKES, Heather A, DEGEEST, Koen, BRISTOW, Robert E, MUTCH, David, YAMADA, S. Diane, COHN, David, CALVERT, Valerie, FARLEY, John

“…PURPOSE Sorafenib is a kinase inhibitor targeting Raf and other kinases (ie, vascular endothelial growth factor receptor [VEGFR], platelet-derived growth…”
Get full text

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer by Leslie, Kimberly K, Sill, Michael W, Lankes, Heather A, Fischer, Edgar G, Godwin, Andrew K, Gray, Heidi, Schilder, Russell J, Walker, Joan L, Tewari, Krishnansu, Hanjani, Parviz, Abulafia, Ovadia, Rose, Peter G

“…Abstract Objective A phase II trial was performed to evaluate the efficacy and safety of the tyrosine kinase inhibitor of epidermal growth factor receptor…”
Get full text

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062) by Tewari, Krishnansu S, Sill, Michael W, Monk, Bradley J, Penson, Richard T, Moore, David H, Lankes, Heather A, Ramondetta, Lois M, Landrum, Lisa M, Randall, Leslie M, Oaknin, Ana, Leitao, Mario M, Eisenhauer, Eric L, DiSilvestro, Paul, Van Le, Linda, Pearl, Michael L, Burke, James J, Salani, Ritu, Richardson, Debra L, Michael, Helen E, Kindelberger, David W, Birrer, Michael J

“…To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and…”
Get full text

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study by Farley, John, Sill, Michael W, Birrer, Michael, Walker, Joan, Schilder, Russell J, Thigpen, J. Tate, Coleman, Robert L, Miller, Brigitte E, Rose, Peter G, Lankes, Heather A

“…Abstract Background The purpose of this study was to evaluate the safety and efficacy of cetuximab (C225), an antibody that inhibits epidermal growth factor…”
Get full text

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study by Coleman, Robert L, Sill, Michael W, Lankes, Heather A, Fader, Amanda Nickles, Finkler, Neil J, Hoffman, James S, Rose, Peter G, Sutton, Gregory P, Drescher, Charles W, McMeekin, D. Scott, Hu, Wei, Deavers, Michael, Godwin, Andrew K, Alpaugh, R. Katherine, Sood, Anil K

“…Abstract Objectives Aflibercept targets vascular endothelial growth factor and placental growth factor. We evaluated activity and toxicity of aflibercept in…”
Get full text

A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D by Hyman, David M, MD, Sill, Michael W, PhD, Lankes, Heather A, PhD, Piekarz, Richard, MD, PhD, Shahin, Mark S, MD, Ridgway, Mildred R, MD, Backes, Floor, MD, Tenney, Meaghen E, MD, Mathews, Cara A., MD, Hoffman, James S, MD, Aghajanian, Carol, MD, PhD, Hensley, Martee L, MD

“…Abstract Objective This two-stage Phase II study assessed the activity of single agent alisertib in patients with recurrent/persistent uterine leiomyosarcoma…”
Get full text

Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study by Devor, Eric J., Miecznikowski, Jeffrey, Schickling, Brandon M., Gonzalez-Bosquet, Jesus, Lankes, Heather A., Thaker, Premal, Argenta, Peter A., Pearl, Michael L., Zweizig, Susan L., Mannel, Robert S., Brown, Amy, Ramirez, Nilsa C., Ioffe, Olga B., Park, Kay J., Creasman, William T., Birrer, Michael J., Mutch, David, Leslie, Kimberly K.

“…•This study screened for miRNAs associated with endometrial cancer recurrence.•We profiled miRNAs from the three major endometrial cancer subtypes in…”
Get full text

A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study by McCourt, Carolyn K., MD, Deng, Wei, PhD, Dizon, Don S., MD, Lankes, Heather A., PhD MPH, Birrer, Michael J., MD PhD, Lomme, Michele M., MD, Powell, Matthew A., MD, Kendrick, James E., MD, Saltzman, Joel N., MD, Warshal, David, MD, Tenney, Meaghan E., MD, Kushner, David M., MD, Aghajanian, Carol, MD

“…Abstract Background The primary objectives were to determine the objective response rate (ORR) and safety profile of ixabepilone in women with recurrent or…”
Get full text

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study by Schilder, Russell J, Brady, William E, Lankes, Heather A, Fiorica, James V, Shahin, Mark S, Zhou, Xun C, Mannel, Robert S, Pathak, Harsh B, Hu, Wei, Alpaugh, R. Katherine, Sood, Anil K, Godwin, Andrew K

“…Abstract Objectives Preclinical data suggest an important role for the sarcoma proto-oncogene tyrosine kinase (SRC) in the oncogenesis of epithelial ovarian…”
Get full text

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study by Garcia, Agustin A, Sill, Michael W, Lankes, Heather A, Godwin, Andrew K, Mannel, Robert S, Armstrong, Deborah K, Carolla, Robert L, Liepman, Marcia K, Spirtos, Nick M, Fischer, Edgar G, Leslie, Kimberly K

“…Abstract Objective Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II…”
Get full text

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study by Gold, Michael A, Brady, William E, Lankes, Heather A, Rose, Peter G, Kelley, Joseph L, De Geest, Koen, Crispens, Marta A, Resnick, Kimberly E, Howell, Stephen B

“…Abstract Purpose This multi-institutional phase II trial assessed the activity and tolerability of the anti-metastatic A6 peptide that binds CD44 in patients…”
Get full text

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008) by Santin, Alessandro D., Filiaci, Virginia, Bellone, Stefania, O’Cearbhaill, Roisin, Ratner, Elena S., Mathews, Cara A., Cantuaria, Guilherme, Gunderson, Camille C., Rutledge, Teresa, Buttin, Barbara M., Lankes, Heather A., Birrer, Michael J.

“…•Endometrial cancer commonly harbors hotspot mutations in the PIK3CA gene.•NRG-GY008 evaluated the activity of copanlisib, an inhibitor of PIK3CA, in recurrent…”
Get full text

Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] by Santin, Alessandro D., Filiaci, Virginia, Bellone, Stefania, O'Cearbhaill, Roisin, Ratner, Elena S., Mathews, Cara A., Cantuaria, Guilherme, Gunderson, Camille C., Rutledge, Teresa, Buttin, Barbara M., Lankes, Heather A., Birrer, Michael J.

“…[This corrects the article DOI: 10.1016/j.gore.2019.100532.]…”
Get full text

Biospecimen Collection During the COVID-19 Pandemic: Considerations for Biobanking by Lankes, Heather A, Makhlouf, Hala

“…Objectives: Millions of biospecimens will be collected during the coronavirus disease 2019 (COVID-19)pandemic. As learned from severe acute respiratory…”
Get full text

In vivo gene delivery and expression by bacteriophage lambda vectors by Lankes, H.A, Zanghi, C.N, Santos, K, Capella, C, Duke, C.M.P, Dewhurst, S

“…Bacteriophage vectors have potential as gene transfer and vaccine delivery vectors because of their low cost, safety and physical stability. However, little is…”
Get full text